Trial Profile

Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary)
Indications Influenza virus infections
Focus Pharmacodynamics; Registrational
Sponsors Sanofi Pasteur

Most Recent Events

13 Jan 2024 Status changed from active, no longer recruiting to completed.
19 Dec 2023 This trial has been completed in Czechia, according to European Clinical Trials Database record.
08 Dec 2023 This trial has been completed in Poland (Trial completion date :2023-10-27), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com